within Pharmacolibrary.Drugs.ATC.L;

model L01XX69
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.20166666666666666,
    adminDuration  = 600,
    adminMass      = 0.0032,
    adminCount     = 1,
    Vd             = 0.504,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Lurbinectedin is an alkylating antineoplastic agent belonging to the tetrahydroisoquinoline family, structurally related to trabectedin. It binds to the minor groove of DNA and inhibits oncogenic transcription, inducing apoptosis in cancer cells. Lurbinectedin is approved for the treatment of metastatic small cell lung cancer (SCLC) in patients who have progressed after prior platinum-based chemotherapy.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult cancer patients after intravenous infusion, no specific stratification by age or sex.</p><h4>References</h4><ol><li><p>Moreno, I, et al., &amp; Lubomirov, R (2024). Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug-Drug Interaction Study. <i>Marine drugs</i> 22(4) –. DOI:<a href=&quot;https://doi.org/10.3390/md22040178&quot;>10.3390/md22040178</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38667795/&quot;>https://pubmed.ncbi.nlm.nih.gov/38667795</a></p></li><li><p>Metaxas, Y, et al., &amp; Stathis, A (2022). A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors. <i>Investigational new drugs</i> 40(1) 91–98. DOI:<a href=&quot;https://doi.org/10.1007/s10637-021-01142-1&quot;>10.1007/s10637-021-01142-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34453241/&quot;>https://pubmed.ncbi.nlm.nih.gov/34453241</a></p></li><li><p>Awada, AH, et al., &amp; Tabernero, J (2022). Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer. <i>ESMO open</i> 7(6) 100651–None. DOI:<a href=&quot;https://doi.org/10.1016/j.esmoop.2022.100651&quot;>10.1016/j.esmoop.2022.100651</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36455505/&quot;>https://pubmed.ncbi.nlm.nih.gov/36455505</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01XX69;
